{"entity":{"id":"nct05147350","kind":"trial","name":"Study of RP-6306 With FOLFIRI in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of Lunresertib run by Debiopharm International SA, terminated.","summary":"Study of RP-6306 With FOLFIRI in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05147350 by Debiopharm International SA, with 38 participants enrolled, started 2022-08-09. Conditions recorded: Advanced Solid Tumor. Interventions recorded: RP-6306 (oral PKMYT1 inhibitor).","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05147350","url":"https://clinicaltrials.gov/study/NCT05147350"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lunresertib"],"companies":["repare-therapeutics","debiopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05147350","phase":"1","setting":"Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors","sponsor":"Debiopharm International SA","enrolled":38,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05147350/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lunresertib","kind":"drug","name":"Lunresertib","route":"/drugs/lunresertib/"}],"company":[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/"},{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/"}]}}